Corbus Pharmaceuticals Holdings, Inc. Proceeds from Notes Payable
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2025-03-11
- Corbus Pharmaceuticals Holdings, Inc. proceeds from notes payable for the quarter ending 2013-12-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. proceeds from notes payable for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. proceeds from notes payable for fiscal 2023 was $373.00K, a 17.52% decline from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. proceeds from notes payable for fiscal 2022 was $452.25K, a 54.06% decline from fiscal 2021.
- Corbus Pharmaceuticals Holdings, Inc. proceeds from notes payable for fiscal 2021 was $984.38K, a 8.25% increase from fiscal 2020.
| Period end | Proceeds from Notes Payable 1 month | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-11 | ||||
| 2023-12-31 | $373.00K 10-K · filed 2025-03-11 | $373.32K 10-K · filed 2024-03-12 | |||
| 2022-12-31 | $452.25K 10-K · filed 2024-03-12 | ||||
| 2021-12-31 | $984.38K 10-K · filed 2023-03-07 | ||||
| 2020-12-31 | $909.38K 10-K · filed 2022-03-08 | ||||
| 2019-12-31 | $963.51K 10-K · filed 2020-03-16 | ||||
| 2018-12-31 | $491.63K 10-K · filed 2020-03-16 | ||||
| 2017-12-31 | $415.26K 10-K · filed 2019-03-12 | ||||
| 2016-12-31 | $348.75K 10-K · filed 2018-03-12 | ||||
| 2015-12-31 | $207.75K 10-K · filed 2018-03-12 | ||||
| 2014-12-31 | $192.00K 10-K · filed 2016-03-28 | ||||
| 2014-10-31 | $192.00K 10-K · filed 2015-02-10 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-10 | $7.25K 10-K · filed 2015-02-10 | |||
| 2013-09-30 | $7.25K 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |